Novel Chemical Probes for Study of 5-HT2R Balance and Function

用于研究 5-HT2R 平衡和功能的新型化学探针

基本信息

项目摘要

The Translational Addiction Sciences Center (TASC) is focused on understanding the role of disrupted serotonin (5-HT) signaling through the 5-HT2A receptor (S-HTZAR) and 5-HT2cR in relapse precipitated by impulsive behavior and craving in the face of cocaine-associated cues (cue reactivity). The mechanisms and neural circuitry through which the 5-HT2AR:5-HT2CR balance controls these behaviors are being explored in Projects 1 and 2, and accumulating data indicate that strategies incorporating combined 5- HT2AR antagonist/5-HT2cR agonist properties will prove particularly effective to suppress impulsivity and cue reactivity and reduce relapse. We have recently demonstrated for the first time that a 5-HT2A+2CR heteromer is found in vitro and ex vivo. These intriguing data raise the wholly-original possibility that these two receptors may directly dimerize and exhibit biochemical properties that are demonstrably distinct from those of its individual components. To explore these hypotheses, new pharmacological tools are required to study the role of 5-HT2AR:5-HT2CR signaling and to elucidate the potential functional impact of 5-HT2R dimerization. Our primary objectives are to develop novel molecules which (1) possess dual activity as a 5-HT2AR antagonist and S-HTacR agonist, and (2) enable structural and functional analyses of 5-HT2R dimerization. Project 3 is taking the novel approach of designing and synthesizing a 5-HT2AR antagonist tethered to a 5-HT2cR agonist; there have been very few cases in which different receptor ligands have been tethered together in an attempt to stimulate one receptor while blocking the other. The molecules synthesized in this Project will be used to study the biology of these proteins and will have the ability to bind to specific dimeric receptors and alter their effector pathways selectively (Project 2, Core B). Biotinylated and fluorescently-labeled molecules will also be synthesized to visualize the location and formation of receptor dimers in vitro and ex vivo. In addition to synthesizing selective bivalent ligands at the bench, an in vivo synthetic approach, using reactions templated by receptor dimers, will be developed to probe receptor dimerization and provide novel, new bivalent ligands. Achievement of these Aims will provide us with novel and innovative pharmacological tools necessary to conduct detailed analyses of the impact of 5-HT2A+2CR heterodimerization on the balance of 5-HT2R function, and to test the overarching hypothesis that pharmacological restoration of 5-HT2AR:5-HT2CR balance will minimize deleterious behaviors that promote relapse in cocaine dependence. R E L E V A N C E (See instructions): The need for new tools and proof-of-principle for therapeutics development is vitally translational and we will direct these efforts toward the creation of targeted serotonergic molecules with fundamentally new mechanisms of action for treatment of cocaine addiction.
转化成瘾科学中心(TASC)专注于理解中断的作用

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SCOTT R GILBERTSON其他文献

SCOTT R GILBERTSON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SCOTT R GILBERTSON', 18)}}的其他基金

Pilot Scale Libraries Based on Biologically Active Scaffolds
基于生物活性支架的中试规模文库
  • 批准号:
    7758425
  • 财政年份:
    2010
  • 资助金额:
    $ 26.14万
  • 项目类别:
Pilot Scale Libraries Based on Biologically Active Scaffolds
基于生物活性支架的中试规模文库
  • 批准号:
    8076724
  • 财政年份:
    2010
  • 资助金额:
    $ 26.14万
  • 项目类别:
Pilot Scale Libraries Based on Biologically Active Scaffolds
基于生物活性支架的中试规模文库
  • 批准号:
    8272696
  • 财政年份:
    2010
  • 资助金额:
    $ 26.14万
  • 项目类别:
NOVEL PROBES FOR THE STUDY OF 5-HT2R NEUROBIOLOGY
用于研究 5-HT2R 神经生物学的新型探针
  • 批准号:
    7680203
  • 财政年份:
    2008
  • 资助金额:
    $ 26.14万
  • 项目类别:
NOVEL PROBES FOR THE STUDY OF 5-HT2R NEUROBIOLOGY
用于研究 5-HT2R 神经生物学的新型探针
  • 批准号:
    7390002
  • 财政年份:
    2007
  • 资助金额:
    $ 26.14万
  • 项目类别:
Synthesis of Pilot Libraries Based on Medicinal Relevant Scaffolds
基于药物相关支架的中试文库的合成
  • 批准号:
    7921279
  • 财政年份:
    2006
  • 资助金额:
    $ 26.14万
  • 项目类别:
Synthesis of Pilot Libraries Based on Medicinal Relevant Scaffolds
基于药物相关支架的中试文库的合成
  • 批准号:
    7487911
  • 财政年份:
    2006
  • 资助金额:
    $ 26.14万
  • 项目类别:
Synthesis of Pilot Libraries Based on Medicinal Relevant Scaffolds
基于药物相关支架的中试文库的合成
  • 批准号:
    7192186
  • 财政年份:
    2006
  • 资助金额:
    $ 26.14万
  • 项目类别:
Synthesis of Pilot Libraries Based on Medicinal Relevant Scaffolds
基于药物相关支架的中试文库的合成
  • 批准号:
    7287791
  • 财政年份:
    2006
  • 资助金额:
    $ 26.14万
  • 项目类别:
COMBINATORIAL SYNTHESIS OF PHOSPHINE LIGANDS
膦配体的组合合成
  • 批准号:
    7355167
  • 财政年份:
    2006
  • 资助金额:
    $ 26.14万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 26.14万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 26.14万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 26.14万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 26.14万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 26.14万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 26.14万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 26.14万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 26.14万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 26.14万
  • 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
  • 批准号:
    10534864
  • 财政年份:
    2023
  • 资助金额:
    $ 26.14万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了